Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Net revenues
Total net revenues		$ 4,709	$ 933
Cost of sales
Total cost of sales		2,165	516
Gross profit		2,544	417
Operating costs and expenses
Research and development		2,431	3,373
General and administrative		6,371	10,605
Sales and marketing		1,526	3,694
Restructuring and other charges		425	452
Total operating costs and expenses		10,753	18,124
Operating loss		(8,209)	(17,707)
Other income (expenses)
Change in fair value of common stock warrant liability		(4,027)	4,532
Inducement loss on sale of liability classified warrants		(5,197)
Interest expense, net		(38)	(12)
Other income, net		61	147
Net loss		$ (17,410)	$ (13,040)
Net loss per share attributable to common stockholders
Basic		$ (0.23)	$ (0.39)
Diluted		$ (0.24)	$ (0.39)
Weighted average shares outstanding
Basic	[1]	76,158,275	33,019,994
Diluted		76,396,078	33,019,994
Product [Member]
Net revenues
Total net revenues		$ 1,729	$ 428
Cost of sales
Total cost of sales		241	340
Service [Member]
Net revenues
Total net revenues		2,980	505
Cost of sales
Total cost of sales		$ 1,924	$ 176

[1] In December 2020 and January 2021, the Company sold pre-funded warrants to purchase up to 5,238,043 and 2,420,910 shares of common stock, respectively. The shares of common stock associated with the pre-funded warrants are considered outstanding for the purposes of computing earnings per share prior to exercise because the shares may be issued for little or no consideration, are fully vested, and are exercisable after the original issuance date. The pre-funded warrants sold in December 2020 and January 2021 were exercised during the period and included in the denominator for the period of time the warrants were outstanding.